๐ฃ๐ฟ๐ฒ๐๐ ๐ฅ๐ฒ๐น๐ฒ๐ฎ๐๐ฒ: ๐๐บ๐บ๐๐ป๐ผ๐ฃ๐ฟ๐ฒ๐ฐ๐ถ๐๐ฒ ๐ฎ๐ป๐ป๐ผ๐๐ป๐ฐ๐ฒ๐ ๐๐-๐ฑ๐ฟ๐ถ๐๐ฒ๐ป ๐ฏ๐ฟ๐ฒ๐ฎ๐ธ๐๐ต๐ฟ๐ผ๐๐ด๐ต ๐ถ๐ป ๐๐ป๐ถ๐๐ฒ๐ฟ๐๐ฎ๐น ๐ฑ๐ฒ๐ป๐ด๐๐ฒ ๐๐ฎ๐ฐ๐ฐ๐ถ๐ป๐ฒ ๐ฑ๐ถ๐๐ฐ๐ผ๐๐ฒ๐ฟ๐
Excited to share a breakthrough in #Dengue vaccine discovery from ImmunoPrecise Antibodies. Our AI-powered LENSแตโฑโข platform identified a highly conserved epitope across all four dengue virus serotypesโa step forward for global health. Congratulations to Jennifer Bath, Ph.D. and the @BioStrandBV team, and thank you to organizations like @WHO , @gavi , @PATHtweets, @CDCgov , and @NIH for leading the global fight against infectious diseases.
๐ฆ๐ฒ๐ฒ ๐๐ต๐ฒ ๐ณ๐๐น๐น ๐ฟ๐ฒ๐น๐ฒ๐ฎ๐๐ฒ: https://t.co/l3Hx0ei9UT
$IPA #WorldHealth #VaccineDiscovery #AIinBiotech #InfectiousDiseases #GlobalHealth
iFabric Corp
As per company update below, sounds like a decent q4 will be reported and that q1 is going to be strong.
Gross margin slowly improving as well as profitability.
US expansion ongoing and FY25 should be another record year.
I find it interesting here and no one seems to be paying attention. As always, do your own due diligence.
iFabric Corp. Announces Fifth Consecutive Year of Revenue Growth
https://t.co/51unWOOG49
$IFABF $IFA
Heartbreaking what's happened in Jasper. This was from 2018. You cannot leave vast swaths of standing dead timber and not expect a major fire in time. Our forests are being horribly mismanaged.
BioStrand (an IPA subsidiary) and InterSystems announce they have entered a collaboration to combine technologies to integrate the new vector search capability of the InterSystems IRISยฎ data platform with BioStrand's LENSแตโฑโข platform, setting a new standard for AI-driven applications in healthcare and life sciences.
Read the full release for details: https://t.co/vUx6SXgzAv
$IPA #Innovation #VectorSearch #DataModel #UniversalFoundationAiModel @InterSystems@BioStrandBV
IPA's subsidiary, BioStrand, and its advanced AI Integrated Intelligence platform, LENSแตโฑโข, are now making their mark in the world with companies that provide database management systems. We're honored to receive recognition from InterSystems, an innovative data technology company. Dive into their latest blog to learn more about the latest advancements of the InterSystems IRIS data platform and Vector Search Embeddings, along with their promising possibilities with generative AI-based applications.
See the full blog to learn more: https://t.co/UFmijzLEPJ
$IPA #Innovation #AI #ArtificialIntelligence #LLM #VectorEmbedding #DrugDiscovery #Biotechnology #TechBio
I may not know much about cleavelandite (โClโ), but I sure know me some high res video. Here is a better view of @Beyond_Lithium drill core from hole #4 at Ear Falls, EF23-04 in 720p
The project is progressing nicely $BY.C $BYDMF #Lithium#Spodumene#DrillBabyDrill@ONgeology
$IPA @ImmunoPrecise
I thought that was a good PR- acknowledged share price, reaffirmed fundamentals were on track and didnโt create any false expectations . This stock is way oversold, the CRO alone is worth north of $100 million, with no value attributed to #Ai@BioStrandBV ๐ช
IPA appoints 3 new Directors to it's Board of Directors. "The appointees will add complementary skills to the Board's skill matrix, and underline IPAโs commitment to the optimal Board composition. The appointment of Barry A. Springer, Dirk Witters and Chris Buyse to the Board will bring significant experience and expertise to complement the capabilities of the Board, and drive shareholder value." said James Kuo, Board Chair.
See full release for more information as well as the new board bios. https://t.co/W8cH9wQE5s
IPA: The Hub of Biotherapeutic Intelligence
Located at the crossroads of innovation in North America and Europe, IPA stands as a powerhouse in the field of biotherapeutics. This strategic global positioning allows IPA to tap into diverse pools of talent and technology, that not only accelerates antibody discovery but also meet the diverse needs of modern research.
Integrated services:
IPA isn't just an organization; it's a hub of innovation that brings together antibody discovery, artificial intelligence, and protein manufacturing under one umbrella. Our facilities are state-of-the-art hubs where science meets scalability and efficiency.
Ready where you are:
Being situated in the two most advanced research ecosystems globally means IPA can catalyze cross-continental collaborations like never before. Researchers and industry experts are not bound by geographical limitations.
The future is here:
With in vitro, in vivo and in silico research and cutting-edge protein manufacturing techniques, IPA is setting the pace for the future of biotherapeutics.
Join us - where innovation knows no bounds and the future of biotherapeutics is being written today. https://t.co/JYLF5VRoW7
#AntibodyDiscovery #DrugDiscovery #ArtificialIntelligence #AI #Innovation #TechBio #Biotechnology
โIn two years, itโs going to be a rocket to Mars.โ
"The AI train has left the station, and biopharma companies need to climb aboard."
#HYFTs $IPA #IID#ai#LLM#techbio@BioStrandBV @ImmunoPrecise
https://t.co/kBXGzadaxh